Clinical Genitourinary Cancer
IF
2.69
Papers
1681
Papers 1830
1 page of 183 pages (1,830 results)
Newest
#1Aruz Mesci (McMaster University)
#2Naghmeh Isfahanian (McMaster University)H-Index: 2
Last. Theodoros Tsakiridis (McMaster University)H-Index: 27
view all 5 authors...
Abstract null null High risk prostate cancer (HR-PrCa) is a subset of localized PrCa with significant potential for morbidity and mortality associated with disease recurrence and metastasis. Radiotherapy combined with Androgen Deprivation Therapy (ADT) has been the standard of care for many years in HR-PrCa. In recent years, dose escalation, hypo-fractionation and high precision delivery with immobilization and image-guidance have substantially changed the face of modern PrCa radiotherapy, impro...
Source
#1Ilker AkarkenH-Index: 6
#2Cenk Yucel Bilen (Hacettepe University)H-Index: 15
Last. Hayrettin SahinH-Index: 9
view all 6 authors...
Abstract null null Introduction null This study aims to investigate whether the calcification of renal arteries and aorta may be risk factors for developing chronic kidney disease (CKD) after Nephron sparing surgery (NSS). null null null Materials and Methods null The patients that underwent either open or laparoscopic NSS from 2000 to 2019 in 4 different centers were retrospectively assessed. Of these patients, 328 had a non-contrast-enhanced computer tomography. null Calcium scores of the rena...
Source
#1L. Cerbone (Institut Gustave Roussy)
#2Vincenzo Di NunnoH-Index: 13
Last. Ronan Flippot (Institut Gustave Roussy)H-Index: 13
view all 12 authors...
Abstract null null Background null Cabozantinib, a potent multityrosine kinases inhibitor (TKI), has demonstrated overall survival (OS) benefit over everolimus in patients previously treated with VEGFR TKI for metastatic Renal Cell Carcinoma (mRCC). The efficacy of systemic treatments after cabozantinib failure has not been investigated. null null null Materials and Methods null We conducted a retrospective study on patients receiving systemic treatment after cabozantinib failure in heavily pret...
Source
#1Seok-Soo Byun (Seoul National University Bundang Hospital)H-Index: 30
#2Noh Jin (Seoul National University Bundang Hospital)
Last. Hakmin Lee (Seoul National University Bundang Hospital)H-Index: 7
view all 3 authors...
ABSTRACT null null Background null We compared the clinical outcomes between whole-gland ablation (WGA) and partial gland ablation (PGA) using the high-intensity focused ultrasound (HIFU) technique for localized prostate cancer (PCa). null null null Methods null We retrospectively investigated 206 patients who underwent WGA or PGA for localized PCa. Follow-up prostatic biopsy was performed 1 year postoperatively. We performed intergroup comparison of the postoperative functional and oncological ...
Source
Abstract null null Background null Docetaxel (DOCE) is a standard of care in metastatic castration-resistant prostate cancer (mCRPC). Several retrospective studies suggested a decrease in Prostate Cancer incidence and mortality with metformin (MET). MET has also demonstrated anti-tumor activity in Prostate Cancer preclinical models, with increased apoptosis when added to DOCE. We aimed at exploring the role of MET in combination with DOCE in mCRPC. null null null Patients and Methods null Non-di...
Source
#1Jason Hu (McGill University)H-Index: 3
#2Armen Aprikian (MUHC: McGill University Health Centre)H-Index: 56
Last. Alice Dragomir (McGill University)H-Index: 24
view all 4 authors...
Abstract null null Background null Novel hormonal agents (NHAs) such as abiraterone acetate (ABI) and enzalutamide (ENZ) are frequently used in metastatic castration-resistant prostate cancer (mCRPC). Despite their overall tolerable risk profile, certain signals of cardiovascular toxicity were reported for these agents in clinical trials but little is known about their incidence in clinical practice. The objective was to assess the comparative cardiovascular safety of ABI and ENZ in patients wit...
Source
#1Nathaniel R. Wilson (University of Texas Health Science Center at Houston)H-Index: 4
#2Andrew Wiele (University of Texas MD Anderson Cancer Center)H-Index: 2
Last. Christopher G. Wood (University of Texas MD Anderson Cancer Center)H-Index: 81
view all 12 authors...
Abstract null null Introduction null Renal medullary carcinoma (RMC) is a rare and lethal renal cell carcinoma characterized by the loss of tumor suppressor SMARCB1. Molecular profiling studies have suggested that RMC cells may be vulnerable to therapies that generate DNA damage, such as the combination of the nucleoside analog gemcitabine, and topoisomerase inhibitor doxorubicin. null null null Patients and Methods null We retrospectively analyzed the records of patients with RMC treated with g...
Source
#1Jin Piao (SC: University of Southern California)H-Index: 8
#2John T. Lafin (UTSW: University of Texas Southwestern Medical Center)H-Index: 6
Last. Aditya Bagrodia (UTSW: University of Texas Southwestern Medical Center)H-Index: 32
view all 14 authors...
Abstract null null Objective null : Circulating microRNAs have clear potential for improving malignant germ-cell-tumor (MGCT) diagnosis. Here, we address the central issue of whether measurement of a single microRNA is sufficient for detecting testicular MGCTs, or whether there is added benefit in quantifying other members of the four-microRNA panel previously identified (miR-371a-3p/miR-372-3p/miR-373-3p and miR-367-3p). null null null Patients/Methods null : We performed a pooled analysis of a...
1 CitationsSource
Abstract null null Background null : Cisplatin-based combination chemotherapy before surgery is the standard of care for muscle-invasive bladder cancer. However, the optimal chemotherapy modalities have not been precisely defined to date. null null null Patients and Methods null : In the VESPER trial, patients received after randomization either gemcitabine and cisplatin (GC, 4 cycles) or methotrexate, vinblastine, doxorubicin and cisplatin (dose dense [dd]-MVAC, 6 cycles). Creatinine clearance ...
Source
#1Benedikt Horlemann (UdeM: Université de Montréal)
#2Christoph Würnschimmel (UdeM: Université de Montréal)H-Index: 3
Last. Sharokh F Shariat (MSMU: I.M. Sechenov First Moscow State Medical University)
view all 14 authors...
Introduction null Controversy regarding cancer-specific mortality (CSM) of elderly and very elderly patients with muscle-invasive, non-metastatic, urothelial carcinoma of the urinary bladder (UCUB) undergoing radical cystectomy (RC) vs radiotherapy (RT) still exists. null Materials and methods null In the 2004-2016 Surveillance, Epidemiology and End Results (SEER) database, we identified 2663 UCUB patients aged 75-79 (1808 RC vs 855 RT) and 3569 UCUB patients aged 80-89 (1551 RC vs 2018 RT). Aft...
Source
12345678910
Top fields of study
Cancer
Urology
Surgery
Oncology
Renal cell carcinoma
Prostate cancer
Diabetes mellitus
Medicine